Monitor for follow-up filings to determine if these sales were under 10b5-1 plans; absence of material negative news suggests routine capital activity rather than distress signal.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $24.76entry
- T+1 · 9mo ago −4.68%α −3.77% · $23.60
- T+5 · 8mo ago +0.24%α +1.45% · $24.82
- T+20 · 8mo ago −13.85%α −5.91% · $21.33
- T+60 · 6mo ago −14.74%α −24.07% · $21.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple executives at Arcutis Biotherapeutics sold shares in a coordinated open-market transaction totaling $1.3M across four insiders, representing 0.04% of market cap. These sales coincided with routine stock award grants, a common practice around equity vesting events.
Key Financial Metrics
Key Facts
- Four insiders sold shares open-market for a total of $1,301,102 on March 2, 2026, at ~$25.16 per share
- Sellers include CFO Latha Vairavan and other named executive officers
- On February 27, the same insiders received stock awards totaling 196,000 shares (non-cash, $0 value)
- Total open-market sale value represents 0.04% of $3.1B market cap, below materiality threshold
- Sales appear related to pre-arranged 10b5-1 plans or tax/liquidity management following equity grants
Financial Impact
$1.3M in open-market sales, offset by no direct financial impact from non-cash grants
Risk Factors
- Perception of insider confidence if sales continue beyond planned schedules
- Potential dilution from 196,000 newly granted shares over time
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-ARQT-1772588560985 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers